Analyst Puneet Souda of Leerink Partners maintained a Buy rating on Myriad Genetics (MYGN – Research Report), reducing the price target ...
Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback